Primary completion· ClinicalTrials.gov
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
Glofitamab History and Updates
222 events · 2017 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
3
FDA Approvals
1
Label Revisions
239
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-10Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Glofitamab since 2017, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (1)
2026
- Label revisionColumvi Label Receives Boxed Warning for Cytokine Release Syndrome· Jun 3, 2026
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Trial started· ClinicalTrials.gov
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T
Trial started· ClinicalTrials.gov
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untr
Primary completion· ClinicalTrials.gov
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Primary completion· ClinicalTrials.gov
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Primary completion· ClinicalTrials.gov
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine,
Primary completion· ClinicalTrials.gov
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-
Primary completion· ClinicalTrials.gov
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participan
Primary completion· ClinicalTrials.gov
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Primary completion· ClinicalTrials.gov
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients W
Primary completion· ClinicalTrials.gov
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Trial started· ClinicalTrials.gov
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Primary completion· ClinicalTrials.gov
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Primary completion· ClinicalTrials.gov
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplati
Primary completion· ClinicalTrials.gov
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Primary completion· ClinicalTrials.gov
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab an
Primary completion· ClinicalTrials.gov
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Primary completion· ClinicalTrials.gov
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
Primary completion· ClinicalTrials.gov
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Primary completion· ClinicalTrials.gov
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Primary completion· ClinicalTrials.gov
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T
Primary completion· ClinicalTrials.gov
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untr
Primary completion· ClinicalTrials.gov
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse
Primary completion· ClinicalTrials.gov
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
Primary completion· ClinicalTrials.gov
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CH
Primary completion· ClinicalTrials.gov
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Primary completion· ClinicalTrials.gov
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Primary completion· ClinicalTrials.gov
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL
Primary completion· ClinicalTrials.gov
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Primary completion· ClinicalTrials.gov
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Primary completion· ClinicalTrials.gov
Glofitamab in Chinese Patients With R/R DLBCL
Primary completion· ClinicalTrials.gov
CAR-T Followed by Bispecific Antibodies
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Primary completion· ClinicalTrials.gov
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Primary completion· ClinicalTrials.gov
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Primary completion· ClinicalTrials.gov
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Primary completion· ClinicalTrials.gov
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxalipl
Primary completion· ClinicalTrials.gov
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Primary completion· ClinicalTrials.gov
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With
Primary completion· ClinicalTrials.gov
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Primary completion· ClinicalTrials.gov
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Primary completion· ClinicalTrials.gov
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Primary completion· ClinicalTrials.gov
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Primary completion· ClinicalTrials.gov
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Primary completion· ClinicalTrials.gov
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
Past events
2026
Trial registered· ClinicalTrials.gov
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Label revision· FDA
WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI. Premedicate before each dose, and initiate treatment with the COLUMVI step-up dosing schedule
Trial started· ClinicalTrials.gov
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Trial started· ClinicalTrials.gov
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Trial started· ClinicalTrials.gov
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
Trial registered· ClinicalTrials.gov
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
Trial registered· ClinicalTrials.gov
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
Trial started· ClinicalTrials.gov
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Trial started· ClinicalTrials.gov
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With
Trial registered· ClinicalTrials.gov
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With
Trial started· ClinicalTrials.gov
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Trial started· ClinicalTrials.gov
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
Trial registered· ClinicalTrials.gov
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
Primary completion· ClinicalTrials.gov
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Rel
Trial registered· ClinicalTrials.gov
The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
Trial started· ClinicalTrials.gov
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
Trial started· ClinicalTrials.gov
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Trial started· ClinicalTrials.gov
The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
Trial registered· ClinicalTrials.gov
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Primary completion· ClinicalTrials.gov
Glofitamab in Real Life
Primary completion· ClinicalTrials.gov
Glofitamab in Real Life
Trial registered· ClinicalTrials.gov
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial registered· ClinicalTrials.gov
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Trial registered· ClinicalTrials.gov
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untr
Primary completion· ClinicalTrials.gov
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
Trial registered· ClinicalTrials.gov
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
Trial started· ClinicalTrials.gov
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Trial started· ClinicalTrials.gov
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
2025
Primary completion· ClinicalTrials.gov
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Rela
Trial registered· ClinicalTrials.gov
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
Trial started· ClinicalTrials.gov
Glofitamab in Real Life
Primary completion· ClinicalTrials.gov
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Trial registered· ClinicalTrials.gov
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell L
Trial registered· ClinicalTrials.gov
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
Primary completion· ClinicalTrials.gov
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etopo
Trial started· ClinicalTrials.gov
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Trial started· ClinicalTrials.gov
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Trial started· ClinicalTrials.gov
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
Trial started· ClinicalTrials.gov
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell L
Trial started· ClinicalTrials.gov
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial started· ClinicalTrials.gov
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Trial registered· ClinicalTrials.gov
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
Trial started· ClinicalTrials.gov
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T
Trial started· ClinicalTrials.gov
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Trial started· ClinicalTrials.gov
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Trial started· ClinicalTrials.gov
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Trial registered· ClinicalTrials.gov
Glofitamab in Real Life
Trial started· ClinicalTrials.gov
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Trial started· ClinicalTrials.gov
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Trial started· ClinicalTrials.gov
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse La
Primary completion· ClinicalTrials.gov
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible
Trial registered· ClinicalTrials.gov
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Trial started· ClinicalTrials.gov
Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden
Trial registered· ClinicalTrials.gov
Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden
Trial started· ClinicalTrials.gov
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplati
Trial started· ClinicalTrials.gov
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplati
Trial started· ClinicalTrials.gov
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL
Trial started· ClinicalTrials.gov
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
2024
Trial started· ClinicalTrials.gov
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Primary completion· ClinicalTrials.gov
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP),
Trial started· ClinicalTrials.gov
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Trial started· ClinicalTrials.gov
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients W
Trial started· ClinicalTrials.gov
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-
Trial started· ClinicalTrials.gov
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
Trial registered· ClinicalTrials.gov
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Trial started· ClinicalTrials.gov
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse
Trial registered· ClinicalTrials.gov
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse
Trial registered· ClinicalTrials.gov
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients W
Trial registered· ClinicalTrials.gov
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Trial started· ClinicalTrials.gov
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Trial registered· ClinicalTrials.gov
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-
Trial registered· ClinicalTrials.gov
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse La
Trial started· ClinicalTrials.gov
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
Trial started· ClinicalTrials.gov
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Trial registered· ClinicalTrials.gov
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Trial registered· ClinicalTrials.gov
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
Trial started· ClinicalTrials.gov
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Trial registered· ClinicalTrials.gov
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
Trial registered· ClinicalTrials.gov
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants Wit
Trial registered· ClinicalTrials.gov
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Rela
Trial registered· ClinicalTrials.gov
Glofitamab in Chinese Patients With R/R DLBCL
Trial started· ClinicalTrials.gov
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Trial started· ClinicalTrials.gov
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Rela
Trial started· ClinicalTrials.gov
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Trial registered· ClinicalTrials.gov
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Results posted· ClinicalTrials.gov
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants W
Trial started· ClinicalTrials.gov
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
Trial registered· ClinicalTrials.gov
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Trial started· ClinicalTrials.gov
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Trial registered· ClinicalTrials.gov
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Trial started· ClinicalTrials.gov
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Trial registered· ClinicalTrials.gov
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
Trial started· ClinicalTrials.gov
Glofitamab in Chinese Patients With R/R DLBCL
2023
Trial started· ClinicalTrials.gov
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Primary completion· ClinicalTrials.gov
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Lar
Trial started· ClinicalTrials.gov
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Trial registered· ClinicalTrials.gov
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Trial started· ClinicalTrials.gov
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Trial registered· ClinicalTrials.gov
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Trial registered· ClinicalTrials.gov
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL
Trial registered· ClinicalTrials.gov
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Trial registered· ClinicalTrials.gov
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CH
Trial started· ClinicalTrials.gov
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CH
Trial started· ClinicalTrials.gov
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Rel
Trial started· ClinicalTrials.gov
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Trial started· ClinicalTrials.gov
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
FDA approval· FDA
Sponsor: GENENTECH INC. Class: Type 1 - New Molecular Entity.
Trial registered· ClinicalTrials.gov
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Rel
Trial registered· ClinicalTrials.gov
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Trial registered· ClinicalTrials.gov
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Trial started· ClinicalTrials.gov
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Trial registered· ClinicalTrials.gov
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible
Trial registered· ClinicalTrials.gov
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Trial started· ClinicalTrials.gov
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible
2022
Trial started· ClinicalTrials.gov
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refra
Trial started· ClinicalTrials.gov
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etopo
Trial started· ClinicalTrials.gov
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in P
Primary completion· ClinicalTrials.gov
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractor
Trial registered· ClinicalTrials.gov
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refra
Trial started· ClinicalTrials.gov
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participan
Trial started· ClinicalTrials.gov
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etopo
Trial registered· ClinicalTrials.gov
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Trial started· ClinicalTrials.gov
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine,
Trial started· ClinicalTrials.gov
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants Wit
Trial registered· ClinicalTrials.gov
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants Wit
2021
Trial registered· ClinicalTrials.gov
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in P
Trial started· ClinicalTrials.gov
CAR-T Followed by Bispecific Antibodies
Primary completion· ClinicalTrials.gov
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants W
Trial registered· ClinicalTrials.gov
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine,
Trial registered· ClinicalTrials.gov
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participan
Trial started· ClinicalTrials.gov
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Lar
Trial registered· ClinicalTrials.gov
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Lar
Trial registered· ClinicalTrials.gov
CAR-T Followed by Bispecific Antibodies
Trial started· ClinicalTrials.gov
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxalipl
Trial started· ClinicalTrials.gov
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractor
2020
Trial registered· ClinicalTrials.gov
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractor
Trial started· ClinicalTrials.gov
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Trial started· ClinicalTrials.gov
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Trial started· ClinicalTrials.gov
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants W
Trial registered· ClinicalTrials.gov
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxalipl
Trial registered· ClinicalTrials.gov
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants W
Trial registered· ClinicalTrials.gov
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
2019
Trial registered· ClinicalTrials.gov
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Trial registered· ClinicalTrials.gov
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab an
Trial started· ClinicalTrials.gov
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab an
2018
Trial registered· ClinicalTrials.gov
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-
Trial started· ClinicalTrials.gov
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-
Trial registered· ClinicalTrials.gov
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP),
Trial started· ClinicalTrials.gov
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP),
2017
Trial registered· ClinicalTrials.gov
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single
Trial started· ClinicalTrials.gov
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.